Mallinckrodt said Friday that it has closed the sale of its global Nuclear Imaging business to IBA Molecular for approximately $690 million before tax, including up-front and contingent considerations and the assumption of long-term obligations.
Mallinckrodt’s Nuclear Imaging operations encompass two manufacturing facilities and a total of more than 800 employees in locations across the globe, including nearly 350 in the St. Louis, Mo. area. The entire workforce and the manufacturing facilities have been transferred to IBA Molecular.
The total consideration of $690 million (before tax) consists of $574 million of up-front consideration, the assumption of $39 million of long-term obligations, and $77 million of contingent consideration.